FDA has cleared Vironexis Biotherapeutics Investigational New Drug (IND) application for VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia (ALL). In Q4 2024, Vironexis anticipated launching a phase 1/2 trial for VNX-101, the first AAV-delivered cancer immunotherapy. The trial offered hope for CD19+ ALL patients as VNX-101 had received FTD and Rare Pediatric Disease […]...
FDA Approves TruSight’ Comprehensive Assay...
FDA has approved Illumina for its TruSight Oncology Comprehensive Assay,…
FDA Approves Amneal and Shilpa’s...
FDA has granted Orphan Drug Designation (ODD) to BORUZU™ (bortezomib…
FDA Grants ODD to Abdera’...
FDA has granted Orphan Drug Designation (ODD) to Abdera Therapeutics…